Alzheimer’s disease as well as dementia are two terrible
diseases that not only hurt a patient, they hurt families. Dealing with either
one of these very difficult diseases can take a major toll on everyone
involved. The sad thing is that no amount of diagnostic imaging can really
avoid either and help provide a good strong treatment program that will deal
with either condition.
A CT
scan, MRI scan, and
any other test will reveal that it’s there and what the level it’s in. Now the
FDA has made a move forward in order to work on the monitoring end of things.
Vizamyl has been approved for the purpose of monitoring Alzheimer’s and
dementia. The drug is basically a PET scan tracer that’s
used to create color images for images normally seen in black and white.
The diagnosticimaging.com
article stated that “Many Americans are evaluated every year to determine the
cause of diminishing neurological functions, such as memory and judgment that
raise the possibility of Alzheimer’s disease.” This kind of improvement helps
because although it’s not a cure or a manner of prevention, it definitely aides
in the battle for discovery.
Vizamyl will not tell you what stage Alzheimer’s is in,
nor will it be used to predict whether or not it’s coming. The drug itself is
for scanning purposes, but on the plus side a clear and more accurate scan is
likely to help the patient in a greater way. The battle against Alzheimer’s and
dementia is not likely to change for a long time. It will take much more
research and far greater work to actually make progress.
To be able to see a colorful image and better interpret
it is a step in the proper direction and hopefully it will mean that in the end
better things will lie ahead. If you have any questions about diagnostic
imaging procedures please feel free to give us a call. Our team of dedicated
imaging professionals here at Clermont Radiology looks forward to answering all
your questions and aiding you in your imaging needs.
No comments:
Post a Comment